1. Home
  2. TIC vs MESO Comparison

TIC vs MESO Comparison

Compare TIC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TIC

Acuren Corporation

HOLD

Current Price

$8.53

Market Cap

1.9B

Sector

N/A

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.52

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TIC
MESO
Founded
1991
2004
Country
United States
Australia
Employees
6060
81
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TIC
MESO
Price
$8.53
$15.52
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$11.20
N/A
AVG Volume (30 Days)
2.7M
212.7K
Earning Date
05-06-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$44.09
$629.74
Revenue Next Year
$4.40
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.36
$9.88
52 Week High
$14.94
$21.50

Technical Indicators

Market Signals
Indicator
TIC
MESO
Relative Strength Index (RSI) 57.83 50.91
Support Level $6.55 $14.44
Resistance Level $9.88 $16.37
Average True Range (ATR) 0.42 0.48
MACD 0.21 0.10
Stochastic Oscillator 70.97 61.26

Price Performance

Historical Comparison
TIC
MESO

About TIC Acuren Corporation

TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: